AK

Andrei Kirillov

Active Director Director DIN 11981558
DIN 11981558 First appointment Oct 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Andrei Kirillov

Andrei Kirillov is a Director at Nirani Gbi Biotech Private Limited (since 2026).

DIN 11981558
Primary Designation Director
First Appointment 01 Oct 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Nirani Gbi Biotech Private Limited U20131KA2026PTC229042
Director01 Oct 20262026Active

Board colleagues of Andrei Kirillov

Directorship timeline

Open interactive timeline →
Nirani Gbi Biotech Private Limited
Premium access

Shareholding and investment profile for Andrei Kirillov

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Andrei Kirillov

Andrei Kirillov currently holds 1 directorship: Nirani Gbi Biotech Private Limited (Director, since 01 Oct 2026).

Andrei Kirillov was first appointed on 01 Oct 2026 as Director at Nirani Gbi Biotech Private Limited.

The current boards of Andrei Kirillov's companies include Kamala Murigeppa Nirani (Nirani Gbi Biotech Private Limited), Murgesh Rudrappa Nirani (Nirani Gbi Biotech Private Limited), Sangamesh Nirani (Nirani Gbi Biotech Private Limited), Shreya Vishal Nirani (Nirani Gbi Biotech Private Limited), Theodorus Everwijn (Nirani Gbi Biotech Private Limited), Vijaykumar Murugesh Nirani (Nirani Gbi Biotech Private Limited), among others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available